Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-000568-28
    Sponsor's Protocol Code Number:GO28888
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-05-22
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2013-000568-28
    A.3Full title of the trial
    A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY OF NEOADJUVANT LETROZOLE PLUS GDC-0032 VERSUS LETROZOLE PLUS PLACEBO IN POSTMENOPAUSAL WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER
    ESTUDIO DE FASE II ALEATORIZADO, DOBLE CIEGO, DE LETROZOL MÁS GDC-0032 VERSUS LETROZOL MÁS PLACEBO EN NEOADYUVANCIA PARA MUJERES POSTMENOPÁUSICAS CON CÁNCER DE MAMA EN ESTADIO INICIAL POSITIVO PARA RECEPTORES DE ESTRÓGENOS Y HER2-NEGATIVO
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Randomized trial in postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer in the presurgical setting to test whether the addition of GDC-0032 to letrozole gives added benefit
    Estudio aleatorizado en mujeres postmenopausicas con cancer de mama positivo para receptores de estrogenos y Her2 negativo en estado prequirurgico para comprobar si la adición de GDC-0032 a letrozol aporta beneficio añadido.
    A.4.1Sponsor's protocol code numberGO28888
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorRoche Farma S.A en nombre de Genentech, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGenentech Inc. c/o F. Hoffmann-La Roche Ltd
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGenentech Inc. c/o F. Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number--+34 913257300-
    B.5.5Fax number----
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGDC-0032
    D.3.2Product code RO 553-7381/F07
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNtaselib
    D.3.9.1CAS number -
    D.3.9.2Current sponsor codeGDC-0032
    D.3.9.3Other descriptive nameRO5537381
    D.3.9.4EV Substance CodeSUB61505
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLetrozole
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLETROZOLE
    D.3.9.1CAS number 112809-51-5
    D.3.9.4EV Substance CodeSUB08444MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER
    Mujeres con cancer de mama en estadio inicial con RE positivos y Her2 negativo
    E.1.1.1Medical condition in easily understood language
    Early Breast cancer
    cancer de mama precoz
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level LLT
    E.1.2Classification code 10070575
    E.1.2Term Estrogen receptor positive breast cancer
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    primary objective of this study is to evaluate the efficacy of letrozole plus GDC-0032 versus letrozole plus placebo in women with ER+/HER2- early stage breast cancer, as measured by the following co-primary endpoints:
    -Tumor overall objective response rate (ORR) by centrally assessed breast magnetic resonance imaging (MRI) via modified Response Evaluation Criteria in Solid Tumors (RECIST) in all enrolled patients and PIK3CA MT patients
    -pCR rate in breast and axilla (ypT0/Tis ypN0) by local evaluation in all enrolled patients and PIK3CA MT patients
    El objetivo principal de este estudio es evaluar la eficacia de letrozol más GDC-0032 versus letrozol más placebo en mujeres con RE+/Her2- en cancer de mama en estadio precoz, determinado por los siguientes criterios coprincipales de valoración:
    -Tasa de respuesta objetiva global tumoral (TRO) mediante resonancia magnética (RM) de mama evaluada de forma central con los Criterios modificados de evaluación de la respuesta en tumores sólidos (RECIST) en todas las pacientes incluidas y en las pacientes con mutación (MT) del gen PIK3CA.
    - Tasa de respuesta patológica completa (RPC) en la mama y en la axila (ypT0/Tis ypN0) según evaluación local en todas las pacientes incluidas y en las pacientes con MT del gen PIK3CA.
    E.2.2Secondary objectives of the trial
    The secondary efficacy objectives of this study are the following:
    -Tumor ORR, assessed by centrally assessed breast MRI via modified Response Evaluation Criteria in Solid Tumors (RECIST) in PIK3CA WT patients
    -pCR rate in breast and axilla (total pCR ypT0/Tis ypN0) by local evaluation in PIK3CA WT patients
    Los objetivos secundarios de eficacia de este estudio son los siguientes:
    - Tasa de respuesta objetiva tumoral (TRO) evaluada mediante resonancia magnética (RM) de mama evaluada de forma central con los Criterios modificados de evaluación de la respuesta en tumores sólidos (RECIST) en las pacientes con PIK3CA de tipo salvaje (WT, wild type)
    -Tasa de RPC en la mama y en la axila (RPC ypT0/Tis ypN0 total) mediante evaluación local en las pacientes con PIK3CA de WT
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Histologically confirmed invasive breast carcinoma, with all of the following characteristics:
    - Primary tumor >= 2 cm in largest diameter (cT1-3) by MRI. In the case of a multifocal tumor (defined as the presence of two or more foci of cancer within the same breast quadrant), the largest lesion must be >= 2 cm and designated as the ?target? lesion for all subsequent tumor evaluations.
    - Stage I to operable Stage III breast cancer
    - Documentation confirming the absence of distant metastasis (M0) as
    determined by institutional practice (in patients where there may be a
    reasonable suspicion of advanced disease e.g., large tumors, clinically positive axillary lymph nodes, signs and symptoms).
    - ER-positive and HER2-negative breast cancer, as per local laboratory or regional definition
    - Breast cancer eligible for primary surgery
    - Tumor tissue from FFPE core biopsy of breast primary tumor that is confirmed as evaluable for PIK3CA mutation status by central histopathology laboratory
    - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    - Fasting glucose <=125 mg/dL
    - Adequate hematological, renal, and hepatic function, as follows:
    - Absolute neutrophil count >= 1500/?L
    - Platelets count >=100,000/?L
    - Carcinoma de mama invasivo confirmado histológicamente, con todas las características siguientes:
    - Tumor primario >= 2 cm de diámetro mayor (cT1-3) mediante una RM. En caso de un tumor multifocal (definido como la presencia de dos o más focos de cáncer en el mismo cuadrante de la mama), la lesión mayor debe ser >= 2 cm y se considerará la lesión objetivo para todas las evaluaciones tumorales posteriores.
    - Cáncer de mama en estadio I a estadio III operable
    - Documentación que confirme la ausencia de metástasis a distancia (M0), determinada según la práctica del centro (en pacientes en las que exista una sospecha razonable de enfermedad avanzada, p. ej., tumores grandes, ganglios linfáticos axilares positivos clínicamente, signos y síntomas).
    - Cáncer de mama positivo para ER y HER2-negativo, según el laboratorio local o la definición regional.
    - Cáncer de mama apto para cirugía primaria.
    - El tejido tumoral de una muestra FFIP obtenida mediante biopsia del tumor de mama primario debe estar confirmado como evaluable para el estado de mutación de PIK3CA mediante el laboratorio histopatológico central
    -Función hematológica,renal y hepática adecuada, según lo siguiente:
    - Recuento absoluto de neutrófilos >=1500/?l
    ? Cifra de plaquetas >= 100000/?l
    E.4Principal exclusion criteria
    -Any prior treatment for primary invasive breast cancer
    -Patients with cT4 or cN3 stage breast tumors
    -Metastatic (Stage IV) breast cancer
    -Bilateral invasive breast cancer
    -Multicentric breast cancer (the presence of more than one tumor in different quadrants of the breast)
    -Patients who have undergone excisional biopsy of primary tumor and/or axillary lymph nodes.
    - Patients for whom upfront chemotherapy is clinically judged appropriate as optimal neoadjuvant treatment
    - Patients for whom immediate surgery is indicated.
    -Patients who have undergone sentinel lymph node biopsy prior to study treatment
    -Type 1 or 2 diabetes requiring antihyperglycemic medication
    -Inability or unwillingness to swallow pills
    -Malabsorption syndrome or other condition that would interfere with enteric absorption.
    - DLCO <60% of the predicted values (see Appendix 7 for calculations)
    -Cualquier tratamiento previo para cáncer de mama invasivo primario.
    - Pacientes con tumores de mama en estadio cT4 o cN3.
    - Cáncer de mama metastásico (estadio IV).
    - Cáncer de mama invasivo bilateral.
    - Cáncer de mama multicéntrico (presencia de más de un tumor en diferentes cuadrantes de la misma mama).
    - Pacientes en las que se haya realizado una biopsia escisional del tumor primario y/o de los ganglios linfáticos axilares.
    - Pacientes en las que se haya realizado una biopsia del ganglio linfático centinela antes del tratamiento del estudio.
    - Pacientes que requieran quimioterapia neoadyuvante según criterio clínico, como tratamiento neoadyuvante óptimo.
    - Pacientes que requieran una intervención quirúrgica inmediata.
    - Diabetes de tipo 1 o 2 que requiere medicación antihiperglucemiante.
    - Incapacidad o falta de disposición para tragar los comprimidos.
    - Síndrome de malabsorción u otras enfermedades que pudieran interferir en la absorción intestinal.
    - Valores de DLCO <60% de los previstos (véase el anexo 7 para los cálculos)
    E.5 End points
    E.5.1Primary end point(s)
    Co-primary endpoints:
    1) Tumor ORR, assessed by modified RECIST criteria by breast MRI in all enrolled patients and PIK3CA MT patients
    2) Rate of pCR in breast and axilla (total pCR) after completion of study drug in all enrolled patients and PIK3CA MT patients
    criterios coprincipales de valoración:
    - TRO del tumor mediante RM de la mama evaluada centralmente con los criterios RECIST modificados en todas las pacientes incluidas y en las pacientes con MT de PIK3CA.
    - Tasa de RPC en la mama y en la axila (RPC total), mediante tras completar el tratamiento de estudio en todas las pacientes incluidas y en las pacientes con MT de PIK3CA.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1) Tumor ORR evaluated prior to initiating study treatment (baseline) and after completion of study treatment (16 weeks)
    2) pCR evaluated after completion of study treatment (16 weeks)
    1-TRO del tumor evaluado con antelación al inicio del tratamiento de estudio (Basal) y tras completar el mismo (16 semanas)
    2- Tasa de RPC evaluada tras completar el tratamiento de estudio (16 semanas)
    E.5.2Secondary end point(s)
    1) Tumor ORR after completion of study treatment, assessed by modified RECIST criteria by breast MRI in PIK3CA WT patients
    2) Rate of pCR in breast and axilla (total pCR) after completion of study drug in PIK3CA WT patients
    The following will be performed in all enrolled patients and separated by PIK3CA mutation status:
    3) ORR by clinical breast examination, mammography and breast ultrasound
    4) Ki67 values at baseline, Week 3, and surgery
    5) Change in Ki67 from baseline to Week 3; baseline to surgery, and Week 3 to surgery
    6) PEPI score
    7) Change in enhancing tumor volume from baseline to surgery as measured by breast MRI
    8) Evaluation of different definitions of pCR including the following: a) ypT0, ypN0, and b) ypT0/is, ypNX (breast pCR).
    1- TRO del tumor tras completar el tratamiento de estudio, evaluada con los criterios RECIST modificados mediante RM de la mama en pacientes con PIK3CA WT
    2-Tasa de RPC en mama y axila (RPC total) tras completar el tratamiento de estudio en pacientes con PIK3CA WT
    Los siguientes se evaluarán en todas las pacientes incluidas y por separado según el estado de mutación de PIK3CA:
    3- TRO mediante examen clínico de la mama, mamografía y ecografía mamaria
    4- niveles de Ki67 a nivel basal, semana 3 y momento de cirugia
    5- Cambios en Ki67desde basal a semana 3, de basal a cirugia y de semana 3 a cirugia
    6- Indice PEPI
    7- cambios en el volumen tumoral desde el periodo basal hasta el momento de la cirugía determinados mediante RM de la mama.
    8- Evaluar las diferentes definiciones de RPC, incluidas las siguientes: a) ypT0, ypN0 y b) yoT0/is, ypNX (RPC en la mama).
    E.5.2.1Timepoint(s) of evaluation of this end point
    For secondary endpoints involving ORR and change in enhancing tumor volume, timepoints are prior to initiating study treatment and after completion of study treatment (16 weeks). For pCR and PEPI score, timepoint is completion of study treatment (16 weeks). For Ki67 analyses, timepoints are as listed with surgery occurring within 1 week of completion of the study treatment (16 weeks).
    Para los criterios secundarios de valoración correspondientes a TRO y cambios en el volumen tumoral, los tiempos son previos al inicio del tratamiento de estudio y tras completar el mismo (16 semanas ).
    Para analisis de Ki67, los tiempos vendrán dados cuando tenga lugar la cirugia dentro de 1 semana de plazo tras completar el tratamiento de estudio (16 semanas)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned17
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA70
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Austria
    Belgium
    Czech Republic
    France
    Germany
    Hungary
    Italy
    Korea, Republic of
    Poland
    Portugal
    Russian Federation
    Spain
    Switzerland
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date when the last patient has her postsurgery visit. The total duration of the study is expected to be approximately 24 months for enrollment, plus 5.5 months after last patient in.
    El fin de estudio se define como la fecha de la visita postcirugia del último paciente. La duración total del estudio se prevee sea de aproximadamente de 24 meses para el reclutamiento, más 5,5 meses tras el ultimo paciente incluido.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days15
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days15
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 198
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 132
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state82
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 330
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The Sponsor will offer post-trial access to the study drug (GDC-0032, letrozole, or other study interventions) free of charge to eligible patients.
    El promotor ofrecerá el acceso al tratamiento (GDC-0032, letrozol, u otra alternativa de estudio) tras el ensayo, libre de cargo a pacientes elegibles.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-05-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-05-20
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2017-03-13
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA